Funds raised will provide diabetes medication for companion animals
PORTLAND, Maine--(BUSINESS WIRE)-- In recognition of National Diabetes Month, Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, will donate $1 to The Pet Fund® for every order that includes a featured diabetes care product throughout November. The funds raised will be used to help pet owners manage their cat or dog’s diabetes with testing, medication and education. Covetrus, in partnership with Boehringer Ingelheim, Nestle Purina Petcare, UltiMed and Zoetis, has committed to donating as much as $20,000 for this initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005113/en/
Receiving a diagnosis of diabetes for a companion animal can be an emotional and financially overwhelming experience for pet owners. In recognition of National Diabetes Month, Covetrus® will donate $1 to The Pet Fund® for every order that includes a featured diabetes care product throughout November. The funds raised will be used to help pet owners manage their cat or dog’s diabetes with testing, medication and education. (Photo: Business Wire)
“We are pleased to have the support of Covetrus in helping pet owners understand and manage diabetes in companion animals,” said Karen Leslie, executive director of The Pet Fund, a registered national nonprofit organization that is dedicated to funding non-basic, non-urgent veterinary care for those who cannot afford it. “Our combined efforts will help pet owners be more successful in treating canine and feline diabetes, as well as keeping companion animals out of shelters and in loving homes.”
Diabetes is a disease caused by the lack of insulin that regulates blood-sugar levels. Historically, it has gone undiagnosed in companion animals, but the prevalence of diabetes has increased dramatically in recent years. Receiving a diagnosis of diabetes for a companion animal can be an emotional and financially overwhelming experience for pet owners. For some pet owners veterinary care for diabetes is beyond their means, leading to economic euthanasia or surrendering to a pet shelter. The Pet Fund helps companion pet owners afford veterinary care by providing grants for testing and medication. The Pet Fund also provide education for proper pet diabetes management.
“With regular veterinary care and education, diabetes management in companion animals is possible, and can result in greater quality of life for the pet,” said Davey Stone, national director of specialty markets and corporate philanthropy at Covetrus. “Which is why we are grateful to have the collaborative support of our partners to enable more veterinarians to provide clients with life-saving funding opportunities from The Pet Fund.”
About Covetrus Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. For more information about Covetrus visit https://www.covetrus.com.
Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the SEC. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.